A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
PDL BioPharma Inc. (NASDAQ: PDLI) has now shown where its next revenue stream will be coming from. The company announced on Tuesday that it has committed to an equity investment in Noden…
Jon C. Ogg In a recent research report from Jefferies, as they do every week, the analysts highlight their top value ideas to buy now.
Tuesday’s top analyst upgrades, downgrades and initiations include AT&T, Capital One, Cisco, Novartis, Sprint and Starbucks.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Capital One, Energen, Micron Technology, Salesforce.com, United Continental, United Rentals and Viacom.
The top analyst upgrades, downgrades and initiations seen on Wednesday, March 23, include Charles Schwab, Dean Foods, HollyFrontier, Incyte, Newfield Exploration and Nike.
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.
Friday's top analyst calls include Best Buy, 3D Systems, Electronic Arts, Gilead Sciences, Nokia, Shire and United Rentals.
Here are four stocks that will help you sleep easy regardless of how the broader indexes perform for the rest of this year.
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
ThinkstockNovartis AG (NYSE: NVS) is one of the few companies with good news on a major market sell-off. Unfortunately, it is not big enough news to be moving the shares. The Swiss…
Jon C. Ogg Aveo Pharmaceuticals made waves in early trading indications Monday on news of a licensing agreement with Novartis.
Chris Lange ThinkstockThere are times when a negative piece of news in the BioPharma sector can actually help rival companies. Biogen Inc. (NASDAQ: BIIB) is a stock that has been battered of late, and…
Novartis is getting ready to steal a lot of hearts with its newest drug. The FDA has approved Entresto tablets for the treatment of heart failure.
Chris Lange Owning a few top European stocks in a well-balanced portfolio makes good sense at this juncture, especially with the U.S. markets hovering near all-time highs.
